Novo Holdings, Boehringer Ingelheim and Evotec led a $33m Series A round in Centauri Therapeutics.

Novo Holdings, Boehringer Ingelheim and Evotec led a $33m Series A round in Centauri Therapeutics, an immunotherapy company, with participation from Wren Capital. “This investment round is testament to the potential of the Alphamer technology and the progress made to date. The funding will underpin the progression of our AMR efforts, enabling us to identify novel antibacterial candidates and deliver improved treatments for life-threatening infections to the clinic. We will continue to engage with high-calibre investors and grow our team to accelerate these capabilities further," Mike Westby, Centauri Therapeutics Chief Scientific Officer.